The Pharmacokinetics of Grayanotoxin: What Happens in Your Body After a Spoonful of Mad Honey

Why pharmacokinetics matters for a food product

Mad honey is sold as a food, but grayanotoxin is a pharmacologically active molecule that interacts with the same biological targets as cardiac and CNS drugs. Anyone taking it — and certainly anyone prescribing or counseling about it — should understand the ADME profile: Absorption, Distribution, Metabolism, and Elimination.

Below I walk through each stage with the best available data. Where the literature is thin I'll say so, because humility about what we don't know is part of responsible medical writing.

Absorption (A)

Grayanotoxins are lipophilic diterpenes. After oral ingestion they cross the intestinal mucosa passively and enter the portal circulation. First clinical signs — warmth, mild tingling, a slight drop in blood pressure — appear 30 to 90 minutes after ingestion in most case series. Absorption is dose-dependent but also batch-dependent: the honey matrix, fat content, and whether the honey was taken on an empty stomach all shift the onset curve.

Clinical implication: if you consume mad honey with a fatty meal, expect a delayed onset of an additional 30–60 minutes. Do not re-dose during this window.

Distribution (D)

Grayanotoxins distribute widely. Their lipophilicity means they cross the blood–brain barrier readily, which explains the CNS effects (drowsiness, mild confusion, occasional blurred vision) as well as the cardiac effects (bradycardia, hypotension). They do not appear to accumulate in adipose tissue over repeated use, but there is no good long-term pharmacokinetic human data.

The primary pharmacological target is the voltage-gated sodium channel (Na_v), where grayanotoxin binds to site 2 of the alpha subunit and prevents channel inactivation. Sustained sodium influx produces persistent depolarization — which looks clinically like a combination of vagotonic and sympatholytic effects.

Metabolism (M)

Hepatic metabolism appears to be the primary elimination pathway. Animal studies implicate CYP3A4 and CYP2C9 as the main phase I enzymes, with glucuronidation of the hydroxyl groups in phase II. This matters for drug interactions: any medication that strongly inhibits CYP3A4 (grapefruit juice, ketoconazole, erythromycin, ritonavir) will likely prolong and intensify grayanotoxin effects.

Clinical implication: if you are on a strong CYP3A4 inhibitor, treat any dose of mad honey as effectively higher than labeled.

Elimination (E)

Human plasma half-life has not been formally characterized in a published clinical trial. Case reports and symptom-resolution timelines suggest a functional half-life of 8–12 hours. Most patients presenting to emergency departments with grayanotoxin intoxication are hemodynamically normal within 24 hours.

Urinary excretion accounts for a minor portion. Most elimination is via biliary/fecal routes after hepatic metabolism.

What this means for dosing decisions

Three practical takeaways from the ADME profile:

1. The 2-hour re-dose rule. Because peak effect is at 1–3 hours, a conservative re-dose waiting period is at least 2 hours. Re-dosing sooner compounds peak plasma levels unpredictably.
2. The 24-hour safety window. Full symptomatic resolution typically occurs within 24 hours. Residual subclinical effects on cardiac conduction could persist longer, especially in people with pre-existing AV nodal disease.
3. CYP-inhibitor caution. Patients on macrolide antibiotics, azole antifungals, or protease inhibitors should avoid mad honey or use a fraction of the standard dose.

Where the data gaps are

I want to be explicit about what we do not know. There is no published randomized pharmacokinetic study in humans. Plasma half-life estimates come from symptom-resolution curves, not direct assays. The enzyme kinetics data I cited are extrapolated from animal studies of structurally similar diterpenes. Anyone telling you we have precise human PK data on grayanotoxin is overclaiming.

This matters clinically because it means dose-effect variability is higher than for most characterized drugs. A dose that produces mild effects in one person may produce significant bradycardia in another. Start low. Re-dose conservatively.

Bottom line

Grayanotoxin is absorbed within an hour, peaks by three hours, and is mostly cleared within a day. Its lipophilic nature means it distributes widely including to the brain; its hepatic metabolism via CYP3A4 creates interaction potential; and its target (the sodium channel) produces cardiac effects that deserve respect. None of this is reason to fear a conservative dose — but all of it is reason to take the pharmacology seriously before you scale up.